Cipla is focusing on its tirzepatide brand Yurpeak in India's obesity market. Yurpeak has become the second largest GLP-1 product since its launch. The company may not launch generic semaglutide if Yurpeak demand continues. Cipla will re-evaluate semaglutide opportunities in international markets later. Yurpeak's doct…
What this means
This story is part of Rail 24's ongoing investments coverage. We summarise reporting from News so you can quickly scan what changed and why it matters for travellers, commuters and the wider Indian transport sector, then read the full original article at the source. Rail 24 aggregates trusted investments sources and refreshes them continuously so you always see the latest developments in one place.
This investments update was reported by News on and curated by Rail 24. For the complete report, visit the original source below.
More Investments coverage on Rail 24
Rail 24 tracks investments shaping india's railways, airlines, infrastructure and tourism — and global transport sector deals. Browse the latest Investments headlines or jump to all news categories.